38 results about "Platelet storage" patented technology

Compositions, methods, devices and media are provided for platelet storage container that prevents bacterial growth in the stored platelets. The invention relates to blood bank needs in safely storing platelets collected from donors for more than 5 days at room temperature. The container is built with natural adsorbent media that have the characteristics in capturing and killing bacteria and viruses. The stored platelets are isolated from the natural adsorbent material during storage to preserve their medical quality and safety.

Synthetic storage media are disclosed for use in the processing and the storing of platelets. The storage media includes a platelet storage solution and less than 20 percent plasma to preserve platelet function after at least 7 days of storage.

Synthetic platelet storage media is disclosed for use with blood preparations intended for in vivo use. The synthetic platelet storage media is prepared by providing sodium chloride, sodium citrate, sodium acetate and sodium phosphate, and formulating in water 45-120 mM sodium chloride, 5-15 mM sodium citrate, 20-40 mM sodium acetate and 20-30 mM sodium phosphate.

Methods of detecting bacterial contamination in a platelet concentrate are performed using a dynamic light scattering (DLS) instrument and a sample holder. A sample of platelet concentrate can be held vertically or horizontally in a capillary in the sample holder. Alternatively, novel platelet storage bags modified to include an optically translucent window can be held within another variant of the sample holder. Still alternatively, platelet storage bags having one or more tubes detachably appended to the bag can be used. A sample is drawn off into an appended tube for placement directly into the sample holder. This method provides a number of related, non-invasive techniques for detecting whether bacteria has contaminated a platelet concentrate. Contamination indicators include a population of particles different from platelets, microparticles or proteins, bad-quality platelets, i.e. low DLS score, and very high or very low scattering intensity.

Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage, enhancing the survivability of platelets during storage or transfusion and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell surfaces, thereby preventing the assembly of the prothromkinase complex. The modified annexin decreases the binding of leukocytes and platelets during post-ischemic reperfusion, thereby restoring microvascular blood flow and decreasing organ damage. In addition, the modified annexin prevents lipid loss from platelets during storage.

Methods of detecting bacterial contamination in a platelet concentrate are performed using a dynamic light scattering (DLS) instrument and a sample holder. A sample of platelet concentrate can be held vertically or horizontally in a capillary in the sample holder. Alternatively, novel platelet storage bags modified to include an optically translucent window can be held within another variant of the sample holder. Still alternatively, platelet storage bags having one or more tubes detachably appended to the bag can be used. A sample is drawn off into an appended tube for placement directly into the sample holder. This method provides a number of related, non-invasive techniques for detecting whether bacteria has contaminated a platelet concentrate. Contamination indicators include a population of particles different from platelets, microparticles or proteins, bad-quality platelets, i.e. low DLS score, and very high or very low scattering intensity.

The invention discloses a medical PVC material with high oxygen permeability for platelet storage and a preparation method thereof. The material comprises the following components by weight: 100 parts of polyvinyl chloride resin, 45-60 parts of a plasticizer, 5-10 parts of a heat stabilizer, 0.1-2 parts of a lubricant, 0.1-0.5 part of a functional additive of sodium lactate. The invention has the advantages of reasonable formula, stable performance, simple process and low cost, effectively improves the oxygen permeability of platelet storage bag, prolongs the storage life of platelets, and is of great practical significance to the development of medical and health undertakings in our country and even the world.

This invention provides methods for treating cellular blood components and other cells containing mitochondria to improve vital qualities of the cells by contacting the cells with a mitochondrial enhancer to the cells. Mitochondrial enhancers prevent damage to and rejuvenate mitochondria and cells containing mitochondria. Mitochondrial enhancers include alloxazines and related compounds, such as riboflavin. Cells are optionally treated with photoradiation to reduce pathogens with may be present, before, after, and / or during treatment with mitochondrial enhancer. Treating with mitochondrial enhancer enables utilization of higher photoradiation energies, which achieves better pathogen reduction. When platelets are treated with mitochondrial enhancer, treated platelets may be stored for longer times than untreated platelets before they are administered to patients.

Platelet resuspension solutions, platelet storage solutions and systems for processing platelet-containing biological fluids are disclosed, wherein a platelet resuspension solution comprises an aqueous solution having a pH in the range of from about 4 to about 6: dextrose; and citrate; wherein the solution is substantially free of adenine, and wherein a platelet storage solution comprises an aqueous solution having a pH in the range of from about 6.6 to about 7.8; at least one buffer: dextrose, and citrate; wherein the solution is substantially free of adenine.

The invention discloses a platelet oscillation storage box. The platelet oscillation storage box comprises a box body; six rotating cavities which are arranged in an annular array and are communicatedwith each other are formed in the box body; five storage blocks are arranged in each rotating cavity; a storage cavity is formed in each storage block; a placing block is fixedly arranged on the lower end wall of each storage cavity; fixing blocks which are symmetrical up and down are fixedly arranged at the end, close to the center of the array, in each storage cavity; a movable clamping block is arranged between each pair of fixing blocks. According to the platelet oscillation storage box, test tubes in which platelets are stored can be clamped in the storage cavities through clamping devices; and the storage cavities are independent from each other, are in independent communication with a thermostat, so that in fetching or storing of platelet, the constant temperature conditions in a storage cavity to be used are blocked, energy loss is reduced, the constant temperature environments in other storage cavities are not destroyed, platelet storage period is prolonged; and in addition,sealing devices are adopted to maintain the sealing states of the storage cavities, and in oscillation process, locking of sealing covers with the storage cavities is maintained all the time, and thetemperature in the storage cavities is ensured to be constant.

The invention discloses an application of a protein kinase A activator in blood platelet storage and a blood platelet storage method. From the embodiment of the invention, the invention discloses an application of the protein kinase A activator in inhibiting blood platelet apoptosis or keeping the activity of blood platelets for the first time under circumstance that the inducing and adjusting mechanisms of blood platelet apoptosis are unknown. The protein kinase A activator can inhibit afunction induced by blood platelet apoptosis and can prevent the blood platelets from being affected by apoptosis in storage and pathological stress conditions, so that the blood platelet survival time is prolonged. The method is a novel policy of improving the survival period of the blood platelets. The result verifies that determination of service life and survival of the blood platelets by regulating apoptosis has far-reaching significance in prolonging the storage time of the blood platelets, increasing the clinical application efficiency of the blood platelets and preventing the stored blood platelets from being rejected due to afunction of the blood platelets.

A method for storing and using platelets and an associated platelet structure. At least one modified platelet is formed. Each modified platelet includes a platelet and at least one polymerated chemical. Each polymerated chemical includes a polymer covalently bonded directly to the platelet or includes the polymer and a linker molecule such that the linker molecule is covalently bonded to the platelet and the polymer is covalently attached to the linker molecule. The polymer of each polymerated chemical of each modified platelet is polyethylene glycol (PEG) or a PEG derivative. Forming each modified platelet does not include modifying the platelet membrane of each platelet with a glycan-modifying agent. The at least one modified platelet is stored in a temperature range below 0° C. After being stored, the at least one modified platelet may be introduced into a subject to treat a condition related to a reduced platelet function.

Provided in some aspects are methods and compositions for preserving platelets or other cells. In some embodiments, a platelet storage media or cell storage media may comprise a low molecular weight polyethylene glycol (e.g. PEG-400) to allow for extended storage and / or refrigeration of the platelets or cells.

The invention discloses a polyvinyl chloride material with high oxygen permeability and a preparation method thereof. The polyvinyl chloride material with high oxygen permeability comprises the following components in parts by weight: 60 parts of polyvinyl chloride resin with super-high molecular weight, 30-40 parts of polyvinyl chloride resin with middle molecular weight, 40-80 parts of plasticizer TOTM (Trioctyl Trimellitate), 5-20 parts of plasticizer DOA (Dioctyl Adipate), 0-20 parts of plasticizer DOS (Dioctyl Sebacate), 3-10 parts of secondary plasticizer and 0.5-5 parts of calcium and zinc thermal stabilizer. The basic resin used in the material disclosed by the invention is polyvinyl chloride resin which has high oil absorption and is prepared by a super-high molecular weight and middle molecular weight suspension method, the plasticizer TOTM with low mobility is selected, the cold-resistant plasticizers DOA and DOS are compounded in use, and epoxy plant oil plasticizer with the thermal stabilizing effect is used as an assistant, so that the low-temperature resistance and extraction resistance of the product are ensured, and the material has a high gas exchange rate and characteristic of high oxygen permeability and is suitable for blood storage, and particularly suitable for storage of blood platelets. The prepared PVC material with high oxygen permeability can make sure that blood platelets can be stored for 7 days at 22 DEG C, so that the material is suitable for preparation of blood platelet storage bags.

The present invention relates to methods and compositions for reducing sialidase activity and inhibiting bacterial proliferation of one or more bacteria in a platelet product preparation from one or more donors. In general, the method includes contacting the platelet product preparation with an amount of a sialidase inhibitor, to thereby obtain a sialidase inhibitor-treated platelet product preparation. Sialidase activity is reduced and the proliferation of one or more bacteria is inhibited, as compared to a platelet product preparation not subjected to the sialidase inhibitor treatment.

The present invention relates to methods and compositions for reducing sialidase activity and inhibiting bacterial proliferation of one or more bacteria in a platelet product preparation from one or more donors. In general, the method includes contacting the platelet product preparation with an amount of a sialidase inhibitor, to thereby obtain a sialidase inhibitor-treated platelet product preparation. Sialidase activity is reduced and the proliferation of one or more bacteria is inhibited, as compared to a platelet product preparation not subjected to the sialidase inhibitor treatment.

Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.

Certain examples provide systems / apparatus, methods, and articles of manufacture for blood collection / processing instrument operator training and troubleshooting. Certain examples provide a system for platelet resuspension training. The system includes an interactive training application, provided via a mobile device, to train a user to resuspend platelets in a liquid medium prior to its storage and / or transfusion to a patient. The training application is to instruct the user regarding an appropriate motion and vigor for resuspension of platelets in a blood container associated with a blood processing instrument. The system includes a sensor to detect the user's motion of the mobile device. The system includes a processor to compare the user's motion of the mobile device to the appropriate motion and vigor for resuspension of platelets in a blood container and provide feedback to the user regarding the comparison.

The present invention relates to a platelet additive solution (PAS) having an amount of one or more sialidase inhibitors and optionally one or more glycan-modifying agents; and one or more of PAS components that includes a salt, a citrate source, a carbon source, and any combination thereof. The present invention also relates to methods, compositions and kits for increasing the in vivo circulation time of isolated platelets by storing the platelets with one or more sialidase inhibitors. Additionally, the present invention relates to methods and compositions for reducing sialidase activity and inhibiting bacterial proliferation of one or more bacteria in a platelet product preparation from one or more donors.

Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.

The invention discloses a preparing method of mixed concentrated platelets, and belongs to the technical field of medical transfusion. The preparing method comprises the steps of obtaining collected whole blood with a first preset capacity; adopting a centrifugal machine for centrifuging the whole blood under a first preset condition; adopting a blood composition separator for separating plasma layers in the centrifuged whole blood into platelet-poor plasma layers and platelet-rich plasma layers; adopting the blood composition separator for separating albuginea layers in the centrifuged wholeblood; adopting the blood composition separator for transferring platelet-rich plasma into an albuginea layer bag, and obtaining platelet-rich albuginea; putting the platelet-rich albuginea at a preset temperature for storage; repeating the steps above, and obtaining multiple parts of the platelet-rich albuginea with the same blood type; under a second preset condition, obtaining concentrated platelets after centrifugation, and collecting the platelets of the same blood type into a platelet storage blood bag to obtain the mixed concentrated platelets. The preparing method has the technical advantages that the capacity of the mixed concentrated platelets is low, the platelet count can meet the using requirement, and the blood resource is saved.

The invention discloses a platelet preservation method. According to the invention, the influence of different temperatures on the stored platelets is discussed from the aspects of apoptosis and activation of the stored platelets, loss of physiological functions of the platelets, hemostasis thrombus formation ability of the platelets returned to the body and removal efficiency, and finally, the optimal temperature for storing the platelets is selected and is higher than 4 DEG C and not higher than 8 DEG C, preferably 6 DEG C; the platelets stored at the temperature have the best physiological function, the best thrombosis ability and the slowest in-vivo clearing efficiency. Compared with the existing accepted preservation temperature of 4 DEG C and 22 DEG C, the preservation period of the platelets is prolonged, the physiological functions of the platelets are kept to the maximum extent, meanwhile, the requirements of simple and convenient platelet storage method, long-term mass preservation, convenient transportation and the like are met, and the method is suitable for clinical general popularization and application. Meanwhile, the mechanism of apoptosis of the platelets at different preservation temperatures is also researched, and the reasons of apoptosis caused by preservation of the platelets at low temperatures (4 DEG C and 6 DEG C) and 22 DEG C are obtained.

A storage container for pathogen reduction and maintaining pH levels for preserved platelets concentrates and other blood products.

The invention belongs to the technical field of medicines, and in particular relates to a liquid blood platelet storage method and a liquid blood platelet storage device. During storage of a closed space with concentrated or single donor platelets, the temperature is kept to be 22+ / -2 DEG C, and the volume concentration of hydrogen is 3.5 percent; the storage device is a closed constant-temperature device capable of being introduced with hydrogen. According to the storage method and the storage device, the loss of the concentrated or single donor platelets at the temperature of 22+ / -2 DEG C in the storage period can be reduced; due to hydrogen, the activation and CD62p expression level of the platelets can be reduced; the storage injury of the platelets is alleviated, and the in-vitro function of the platelets is enhanced.